BioSpace News Archive

Neurotech Pharmaceuticals, Inc. announces that the U.S. Food and Drug Administration (FDA), has determined that the Biologic License Application (BLA) for NT-501, an investigational encapsulated cell therapy for the treatment of MacTel, is sufficiently complete to permit a substantive review.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of MM120 (lysergic acid diethylamide [LSD] D-tartrate) into pivotal trials for the treatment of adults with GAD.

Zimmer Biomet Holdings, Inc., a global medical technology leader, announced that Devdatt “Dev” Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp., has been appointed to the Zimmer Biomet Board, effective immediately.

Palatin Technologies, Inc. (NYSE American: PTN) announced the initiation of a Phase 2 clinical study of bremelanotide (BMT), a melanocortin 4 receptor (MC4R), co-administered with a phosphodiesterase 5 inhibitor (PDE5i), for the treatment of erectile dysfunction (ED) in patients that do not respond to PDE5i monotherapy.

CellxLife today announced that Eric von Hofe, Ph.D., will serve as the company’s first Chief Executive Officer.

InnoCare Pharma announced today that China National Medical Products Administration (NMPA) has accepted and granted priority review to a biologics license application (BLA) for tafasitamab in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Sanofi and Biovac, a Cape Town, South Africa-based biopharmaceutical company, announce their local manufacturing partnership to produce inactivated polio vaccines in Africa.

Tempest Therapeutics, Inc. announced new positive data from the ongoing global randomized Phase 1b/2 clinical study in which amezalpat2, Tempest’s PPAR⍺ antagonist, delivered a six-month improvement in median overall survival advantage when combined with atezolizumab and bevacizumab in a comparison to atezolizumab and bevacizumab alone in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma.

Mustang Bio, Inc. today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 6,130,000 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.41 per share.

AbbVie (NYSE: ABBV) today announced that the independent directors of the board have selected Roxanne S. Austin as lead independent director, effective July 1, 2024.